SecBot SecBot
PRESS-RELEASE ·Filed Mar 26, 2026

WVE

Wave Life Sciences USA, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Investors should monitor upcoming Phase 2a initiation in 2Q 2026 and further data readouts from higher-dose cohorts. The differentiated profile vs. GLP-1s could position WVE-007 as a maintenance or combination therapy, creating significant commercial upside.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.20
T+0 close · Mar 26, 2026 · via day close
Latest settled
+0.97%
T+60 · $6.26
Vs SPY
−12.98%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 26 $6.20entry
  2. T+1 · 8mo ago +2.74%α +4.42% · $6.37
  3. T+5 · 8mo ago +17.42%α +15.79% · $7.28
  4. T+20 · 7mo ago +15.81%α +5.14% · $7.18
  5. T+60 · 5mo ago +0.97%α −12.98% · $6.26
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Wave Life Sciences released positive Phase 1 data for WVE-007, an investigational obesity treatment, showing significant and durable reductions in visceral fat (-14% vs. placebo) and improved body composition six months after a single dose. The results support advancement into Phase 2a trials in higher-BMI patients in 2Q 2026 and suggest potential in MASH, type 2 diabetes, and cardiovascular disease. The therapy continues to show a favorable safety profile.

Key Facts

  • Single 240 mg dose of WVE-007 led to -14.3% placebo-adjusted reduction in visceral fat at 6 months (p<0.05)
  • Total fat reduced by -5.3%, waist circumference by -3.3%, body weight by -0.9%, with lean mass preserved (+2.4%)
  • Visceral fat-to-muscle ratio (VMR) improved by -16.5%, outperforming semaglutide's -12.2% in a higher-BMI population
  • Serum Activin E suppressed up to 88%, supporting potential for once- or twice-yearly dosing
  • WVE-007 remains generally safe and well tolerated with no severe or serious treatment-related adverse events
  • Phase 2a trial in patients with BMI 35-50 kg/m² expected to initiate in 2Q 2026

Financial Impact

High potential long-term revenue if WVE-007 succeeds in obesity and related metabolic diseases; competitive advantage due to muscle-preserving fat loss and infrequent dosing

revenuevaluationpipeline value

Risk Factors

  • Phase 1 results are in lower-BMI individuals; efficacy may not translate to higher-BMI populations in Phase 2a
  • Development timeline remains long, with key data not expected until 2026-2027
  • Competition from established and emerging obesity therapies is intense

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3262889

Track record

16 reports on WVE

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +4.86% at T+1 after the Sep 30, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.13 to $2.87 Now $2.87 −8.31% ▼ −8.31% −6.40% vs SPY
  2. Oct 27, 202620d ago SC 13G Neutral 4/10 Entry $3.64 to $3.63 Now $2.87 −21.15% ▼ −0.27% +0.11% vs SPY
  3. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
  4. Oct 27, 202620d ago 8-K Bullish 6/10 No price data
  5. Oct 27, 202620d ago Press Release Neutral 5/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
  6. Oct 14, 20264w ago DEF 14A Neutral 4/10 Entry $3.19 to $3.13 Now $2.87 −10.03% ▼ −1.88% −0.77% vs SPY
  7. Sep 30, 20266w ago Press Release Bullish 5/10 Entry $3.70 to $3.88 Now $2.87 −22.43% ▲ +4.86% +4.69% vs SPY
  8. Aug 13, 202613w ago Insider Cluster Neutral 3/10 Entry $5.41 to $5.09 Now $2.87 −46.95% ▼ −5.92% −5.44% vs SPY
  9. May 18, 202626w ago Press Release Bullish 7/10 Entry $6.14 to $6.19 Now $2.87 −53.26% ▲ +0.81% −0.23% vs SPY
  10. Apr 28, 202628w ago 8-K Bullish 7/10 No price data
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 26, 2026